Houston startup raises money, Texas VC closes fund, and more local innovation news

short stories

Here are five quick Houston innovation stories — from fundraising to strategic partnerships. Photo via Getty Images

Houston innovators had no need to beware the ides of March this year. With all the excitement from SXSW, CERAWeek, and Houston Tech Rodeo this month, there might be some headlines you may have missed.

In this roundup of short stories within Houston startups and tech, Houston startups announce new funding and partnerships, while a Texas VC raises its largest fund yet.

Tekmetric closes recent fundraising round

A Houston software company has raised an undisclosed amount of funding. Photo via tekmetric.com

Tekmetric, a cloud-based shop management system for automotive repair shops, announced the close of its growth investment from California-based Susquehanna Growth Equity. The details of the round were not disclosed, but, according to a news release, the fresh funds will go toward growing Tekmetric's engineering and technical teams and expansion across the United States.

Launched three years ago by Prasanth Chilukuri and Sunil Patel, co-founders and co-CEOs, Tekmetric's SaaS solution provides shop owners with digital inspections, integrated payments, and more of their business needs.

“Since our launch in 2016, Tekmetric has always aspired to deliver the greatest possible value to auto repair shop owners who partner with us to run their business,” says Chilukuri in the release. “Susquehanna’s deep industry expertise and support of product-led growth makes the company an ideal partner as we scale our business, boosting our platform’s advanced products and providing the highest caliber of service for our customers.”

The platform provides both convenience and security for its users.

“As a former shop owner myself, I know how difficult it can be to find a system like Tekmetric that shop owners can trust with their business,” says Patel. “At Tekmetric, we strive to build strong relationships with our users to support their business growth. The SGE team has the same mindset, which makes them an ideal partner as Tekmetric continues to grow in the industry.”

The Postage taps new financial planning partner

The Postage has a new strategic partner. Photo courtesy of The Postage

Houston-based legacy and estate planning software platform The Postage has announced a new partnership with Austin-based Whitwell & Co., LLC, an investment management and financial planning firm.

The Postage platform, which will now be available for Whitwell's clients with the new collaboration, range from important information and documents management, estate planning document creation, end-of-life planning, and memory and message storing.

“Whitwell & Co. focuses on supporting their clients through the myriad of choices that arise during planned and unplanned life events and transitions. The Postage fits right into that, and we are thrilled for the opportunity to share our platform with their clients in their planning and organization efforts,” says Emily Cisek, CEO and co-founder of The Postage. “Our hope is to grow awareness of the streamlined digital solutions available and provide Whitwell’s clients the opportunity to create estate planning documents, easily store and safeguard critical information that families will need access at all phases of life. We look forward to providing clients of Whitwell & Co. a comprehensive planning and preparation service that delivers peace of mind to their families.”

The B2B partnership takes effect this month. The Postage, which was founded in 2019, is also closing its crowdfunding campaign on April 4.

“As a company, we are built upon the principles of an innovative approach to investment management and financial planning,” says Stefan Whitwell, CEO at Whitwell & Co. “This partnership is an important approach for us to offer our clients as we progress into the digital age. Having been around families who have had to experience the loss of a loved one, I see the need for a service like The Postage. Too often many are unsure of next steps, where documentation lives, and even last wishes.”

Austin venture capital firm with Houston portfolio companies raised $250M fund

S3 Ventures has fresh funding and eyes for Texas startups. Photo via S3

Billed as the "largest venture capital fund focused on the state of Texas," S3 Ventures's recently announced $250 million Fund VII is focused on investing in Texas startups.

S3 Ventures usually invests $500,000 to $10 million in seed, series A or series B rounds with the capacity to invest more than $20 million throughout the life of a company. The firm has made more than 50 investments since it was founded in 2005 and has more than 25 active portfolio companies and over 20 exits.

“In our first 17 years, we have been fortunate to partner with truly visionary founders who have transformed the way we work, live and heal,” says S3 Managing Director Brian R. Smith in a news release. “We look forward to working with many more in the years ahead.”

The firm has Houston startups in its portfolio: BrainCheck, a provider of interactive cognitive assessment and care planning technology; Saranas, an early bleed detection system; and BuildForce, a construction labor marketplace.

“We believe that by 2030, Texas could be the second-largest technology ecosystem in the country,” Smith said. “That growth is being driven by long-term demographic shifts and broad-based economic strength of not just Austin, but also Dallas, Houston and San Antonio.”

Saranas announces new patent

This Houston medical device company has reached another step in commercialization. Photo courtesy of Saranas

Houston-based early bleed detection medical device company Saranas has been granted a new patent from the Department of Commerce’s United States Patent and Trademark Office. The patent, titled “Access Closure with Bleed Monitoring,” allows for embedding a vascular access closure device with the company’s proprietary bleed monitoring technology.

“As we continue to grow our commercial presence with the Early Bird, we are pleased to secure this important patent that is designed to further expand the implementation of our differentiated bleed monitoring technology,” says Saranas CEO James Reinstein in a news release. “This patent award demonstrates Saranas’ commitment to innovation and further strengthens our intellectual property portfolio.”

At the end of 2021, Saranas announced its first patient in its clinical trials at Morristown Medical Center in Morristown, New Jersey. The trial will eventually enroll up to 265 patients across the U.S.

"We have been using the Early Bird in our clinical practice for the past two years, and the current design of incorporating a fully functional introducer sheath with bleed detection allows for seamless integration into high risk interventional cardiovascular procedures," Dr. Philippe Généreux, interventional cardiologist, says. "Embedding bleed detection directly onto a vascular closure device is the eventual next step and has the potential to become the standard of care across all types of vascular access procedures.”

DECISIO announces new product

DECISIO has a new product on the market. Photo via decisiohealth.com

Houston-based DECISIO has created a suite of customizable clinical decision support tools has announced a new product: EnvisionIQ. The new tool provides templated real-time and customized compliance reports to improve operational efficiency.

EnvisionIQ is a hospital's real-time data and visualization solution enables health systems to benchmark their clinicians, units, and hospitals to accelerate improvements, reduce variation, and expedite data collection for agency reporting requirements.

"Clinical benchmarking tools are essential to enable health systems to quickly identify improvement opportunities that have substantial impact. The addition of EnvisionIQ to our product portfolio allows DECISIO to provide comprehensive surveillance and analytics platforms to benefit hospitals in many capacities," says Paul Sinclair, chief revenue officer at DECISIO, in a news release.

Customers can tap into DECISIO's new product with or without integration with its flagship product, InsightIQTM, which was launched in 2015. The company raised a $13 million series B round in 2019.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Rice researchers score $45M from NIH for cancer-fighting tech

freshly funded

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

TMC again expands global impact with new Netherlands partnership

breaking news

The Texas Medical Center may be based in Houston, but the organization has again grown its global impact.

Since 2016, TMC’s BioBridges have worked with 88 startup companies. Those include strategic alliances with four other countries. Australia, the United Kingdom, Denmark and Ireland are all among TMC’s BioBridges partners. As of today, add the Netherlands to that list.

On September 27, TMC president and CEO, William F. McKeon, and Carmen van Vilsteren, chair of Health~Holland, Top Sector Life Sciences & Health (LSH), signed an agreement in Rotterdam. The TMC Netherlands BioBridge Memorandum of Understanding codifies the innovative goals of the partnership. Essentially, the BioBridge program provides a means for entrepreneurs, researchers, clinicians and industry partners from other countries to access the US market, as well as TMC experts.

“The TMC Netherlands BioBridge represents an unparalleled opportunity for collaboration and growth,” Ashley McPhail, chief external affairs & administration officer at Texas Medical Center said in a press release. “The Netherlands has solidified its position as a global leader in the field of life sciences and health, with a thriving ecosystem of research institutions, innovative companies, and highly skilled professionals. This strategic partnership will bring positive benefits to patients, clinicians and industry partners on a global scale.”

This lifeline for international healthcare companies makes expansion into the United States far smoother. The Global Innovators Launch Pad allows for startup founders to take part in a 10-week residency at the TMC Innovation Factory that will teach them about foundational infrastructure, clinical evidence and funding in the US.

“Since Texas is an important hub for innovation in the MedTech and digital health sectors, the collaboration with Texas Medical Center creates opportunities for Dutch companies looking to expand their international reach. Vice versa, it gives companies in Texas access to the vibrant Dutch Life Sciences & Health sector,” said van Vilsteren.

That exchange includes members of the TMC gaining the opportunity to participate in the Health~Holland Visitors Programme (HVP), “Shaping the Healthcare of the Future.”

The annual event invites high-level representatives from the private sector, NGOs, knowledge institutions, healthcare providers and different tiers of government to share their expertise.

It's the fifth partnership of its kind for TMC, with the last one being with Ireland, announced last year. TMC's other global initiatives include accelerators with Denmark and the United Kingdom, both announced earlier this year.

Houston startup founders prepare to scale globally following Shark Tank success

HOUSTON INNOVATORS PODCAST EPISODE 205

While Milkify's founders — husband and wife team Pedro Silva and Berkley Luck — secured partners on a popular business pitch and investment show, the entire experience almost didn't happen.

Silva and Luck, who got her PhD in molecular and biomedical s at Baylor College of Medicine, founded the company to provide breast milk freeze drying as a service to Houston-area families. Now, Milkify has customers across the country, but the duo didn't know if going through the process would be worth the investment and publicity, or if it would just be a distraction.

"The competitor in me wanted to be the first breast milk company to go on the show and to tell our story to the world — to show the world what my wife came up with that we thought was so great," Silva says on the Houston Innovators Podcast. "It was probably the scariest 45 minutes of my life."

But the sharks bit. Milkify's episode aired in April, and two investors — Gwyneth Paltrow and Lori Greiner — agreed to a $400,000 convertible note for 20 percent equity in the company. Paltrow even said on the show that she would have used the service when she was breastfeeding.

"It was empowering," Luck says of getting to wear her white coat on TV and share the story of how she came up with the idea of Milkify. "It was important to me when we went on the show to express that this had a scientific basis, that we didn't start this lightly, and that we've made huge strides in doing this in the absolute safest way possible."

Silva says they can't talk about some of the details of the show or the deal, but since then, Milkify has reached new customers, received additional investment interest, grown its team, and built out its plan to scale, the founders shared on the podcast. The team also shares its big-picture scale plans, which include tapping international partners to potentially take Milkify's tech global.

"Our vision is for every family to have access to breast milk formula, but instead of re-creating breast milk in a lab, we're doing it with mom's own milk," Silva says, mentioning a partnership with a breast milk bank that will convert its operation from freezing to freeze drying donated milk. "We're also working with groups in the UK and Australia to launch similar services using our patented technology."

"By the end of the year, we hope to see some announcements with those partnerships across the globe."

From the beginning, the importance of Milkify's team has been on supporting working parents to give them the best way to care for their families, Silva says. And for Luck — who says she's proud of the integrity Milkify has at its core despite competitors offering lower-quality and, in some cases, dangerous alternatives — she sees a lot of research benefits for the company.

"It's amazing to be at this leading edge, not just of innovation but of research, and to be able to still put out meaningful advances as an industry partner, not just as an academic," Luck says, adding that she hopes to be able to continue to contribute to the ongoing research into breast milk.

Luck and Silva share more about their Shark Tank experience, their co-founder strengths, and the future of Milkify on the podcast. Listen to the interview here — or wherever you stream your podcasts — and subscribe for weekly episodes.

View All Listings